English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/104092
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Phase i and phase IB clinical trials for the noninvasive evaluation of intestinal lactase with 4-galactosylxylose (gaxilose)

AuthorsHermida, Carmen; Martínez-Costa, Oscar H. CSIC ORCID; Sánchez, Valentina; Fernández-Mayoralas, Alfonso CSIC ORCID ; Aragón, Juan J. CSIC ORCID
Issue Date2013
PublisherLippincott Williams & Wilkins
CitationJournal of Clinical Gastroenterology 47(6): 501-508 (2013)
Abstract[Goals and Background]: Hypolactasia is widespread, yet reliable diagnostic tests are lacking. A new test based on oral administration of 4-galactosylxylose (gaxilose) and urine or serum measurement of D-xylose after cleavage by intestinal lactase is under clinical development. We investigated the optimal dose of gaxilose and calculate cutoff values of D-xylose for that dose. [Study]: In the randomized, dose-finding, phase I study, urine and serum pharmacokinetics of D-xylose were determined after oral administration of 6 ascending doses of gaxilose (and placebo) to 12 healthy adult volunteers. In the open, parallel, phase Ib study, 30 volunteers received the doses established for the urine and blood tests and D-xylose was measured. Cutoff values were calculated as 1.96×SD below the mean value. Safety was assessed through reporting of adverse events. [Results]: Gaxilose administration showed a progressive, dose-dependent increase in D-xylose in urine and serum. An optimal gaxilose dose of 0.45 g and urine collection periods of 4 and 5 hours were selected for further studies. For the blood test, a 2.7 g dose was selected and C max measured at 90 minutes. The calculated cutoff values of D-xylose for normal lactase activity were 27.58 and 37.87 mg for the 4- and 5-hour urine tests, respectively, and 0.97 mg/dL for the blood test. There were no treatment-related adverse events. [Conclusions]: The methodology described provides a simple, safe test for the evaluation of lactase activity in vivo. Further evaluation of the test as a noninvasive diagnosis of hypolactasia is ongoing in patients with lactose intolerance.
Descriptionet al.
URIhttp://hdl.handle.net/10261/104092
DOIhttp://dx.doi.org/10.1097/MCG.0b013e318272f507
Identifiersdoi: 10.1097/MCG.0b013e318272f507
issn: 0192-0790
e-issn: 1539-2031
Appears in Collections:(IQOG) Artículos
(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.